Mahuang-Xixin-Fuzi decoction reduces the infection of influenza A virus in Kidney-Yang deficiency syndrome mice

J Ethnopharmacol. 2016 Nov 4:192:217-224. doi: 10.1016/j.jep.2016.07.017. Epub 2016 Jul 9.

Abstract

Ethnopharmacological relevance: Mahuang-Xixin-Fuzi Decoction (MXF) as a famous formula for the treatment of colds, fever, nasal congestion and headache with elder people, has always been widely used in traditional Chinese medicine. The present study is aimed at investigating the treatment effect of MXF on Kidney-Yang deficiency syndrome in mice simultaneously infected with H1N1 virus.

Materials and methods: We employed the Kidney-Yang deficiency mouse model to investigate the effect of MXF against influenza A virus (A/FM/1/47, H1N1). Mice were infected with the virus after fifteen days Kidney-Yang deficiency syndrome was established (intraperitoneal injection of estradiol benzoate), while MXF was orally administrated with 1.2-4.7g/kg/d for 6 consecutive days after inoculation. Body weight, rectal temperature, morbidity, and mortality were recorded daily. Histopathologic changes, antioxidant activity of SOD and MDA were detected. Moreover, levels of inflammatory cytokines including IL-6, IL-10, MCP-1, TNF-α were measured in the sera of mice.

Results: We found that the extract of MXF at dosages of 2.3-4.7g/kg could effectively diminish mortality rate, ameliorate lung edema and inflammation. Administration of MXF decoction significantly depressed the expression of IL-6, MCP-1 and TNF-α, and markedly increased expression of IL-10 in serum. Simultaneously, the extract was also found to reduce MDA and increase SOD in the lung tissue of mice.

Conclusion: These data support the notion that the extract of MXF could treat Kidney-Yang deficiency syndrome in mice simultaneously infected with influenza A virus by reducing inflammation and increasing antioxidant activities.

Keywords: Antioxidant activity; Inflammatory cytokines; Influenza A virus; Kidney-Yang deficiency syndrome mice; Mahuang-Xixin-Fuzi decoction.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Animals
  • Antioxidants / pharmacology
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology*
  • Chemokine CCL2 / blood
  • Disease Models, Animal
  • Drugs, Chinese Herbal / administration & dosage
  • Drugs, Chinese Herbal / pharmacology*
  • Estradiol / analogs & derivatives
  • Inflammation Mediators / blood
  • Influenza A Virus, H1N1 Subtype / drug effects*
  • Influenza A Virus, H1N1 Subtype / pathogenicity
  • Interleukin-6 / blood
  • Kidney Diseases / blood
  • Kidney Diseases / chemically induced
  • Kidney Diseases / drug therapy*
  • Lung / drug effects
  • Lung / metabolism
  • Malondialdehyde / metabolism
  • Mice
  • Orthomyxoviridae Infections / blood
  • Orthomyxoviridae Infections / drug therapy*
  • Orthomyxoviridae Infections / virology
  • Pulmonary Edema / blood
  • Pulmonary Edema / prevention & control
  • Pulmonary Edema / virology
  • Ribavirin / pharmacology
  • Superoxide Dismutase / metabolism
  • Time Factors
  • Tumor Necrosis Factor-alpha / blood
  • Yang Deficiency / blood
  • Yang Deficiency / chemically induced
  • Yang Deficiency / drug therapy*

Substances

  • Antioxidants
  • Antiviral Agents
  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Drugs, Chinese Herbal
  • Inflammation Mediators
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • interleukin-6, mouse
  • mahuang fuzi xixin
  • estradiol 3-benzoate
  • Ribavirin
  • Estradiol
  • Malondialdehyde
  • Superoxide Dismutase